CTNM
Contineum Therapeutics, Inc.
13.10$
+1.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | -100.0% | – | – | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | -9.9% | -42.5% | – | – | +64.9% | -1.6% | – | – | – | – | +2.5% | +4.9% | -2.4% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -8.1% | +160.5% | -31.3% | +23.3% | -2.9% | +1.6% | +23.1% | +33.8% | +5.4% | +2.6% | -21.8% | +16.0% | -8.7% | +9.0% | – | |
| – | -0.8% | +8.1% | -2.1% | +6.0% | +29.3% | +41.4% | +6.7% | +24.2% | +9.1% | -12.7% | +2.6% | +10.7% | +20.6% | -10.1% | – | |
| – | -6.1% | +116.3% | -27.1% | +19.9% | +2.6% | +10.2% | +18.5% | -753.2% | – | -1.1% | -16.6% | +14.6% | -1.2% | +3.1% | – | |
| – | – | – | -120.7% | – | – | – | – | – | -121.4% | – | – | – | – | – | – | |
| – | -8.9% | +26.1% | -100.0% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -115.1% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -116.2% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -115.0% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -114.9% | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.